Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore from a leading global pharma major.

Supplies under the mandate are expected to commence within the next 4–5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes. This engagement marks one of the most significant single CDMO mandates in the Company’s history, as it scales its global manufacturing footprint.

Built on over four decades of API manufacturing expertise and regulatory credibility, Morepen’s CDMO platform enables deeper collaboration with global pharmaceutical innovators through structured, multi-year supply programs.

The mandate reflects the company’s growing capabilities in regulated markets, supported by internationally accredited facilities including USFDA, WHO-GMP, and EU approvals. With integrated development-to-commercial manufacturing capabilities, Morepen is positioned to support complex scale-ups and long-duration supply frameworks. The company continues to evaluate capacity enhancement and technology investments aligned with its expanding CDMO opportunity pipeline.

Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.